<DOC>
	<DOCNO>NCT00864552</DOCNO>
	<brief_summary>To evaluate long-term safety ( primarily record adverse event include inhibitor ) , efficacy patient acceptance KOGENATE Bayer home treatment either prophylaxis demand . To evaluate safety efficacy respect lot variability , particular regard lot-groups formulate without fix .</brief_summary>
	<brief_title>International PMS Study - KOGENATE Bayer</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients severe haemophilia A ( &lt; 2 % FVIII baseline plasma level ) treat KOGENATE Bayer source recombinant FVIII Exclusion criterion must read conjunction product information ( SmPC )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Recombinant Factor VIII</keyword>
</DOC>